The Global Single-use Upstream Bioprocessing Market is estimated to reach over USD 34.54 billion by 2030, exhibiting a CAGR of 16.6% during the forecast period.
The first step in the bioprocess is upstream bioprocessing, which is used to generate cell lines and cultivate them in order to grow the cells by harvesting. Modern cell growth techniques produce bioreactors with noticeably higher titers, shorter time constraints, and more precision. Upstream manufacturing's main objective is to create the environment necessary for cells to manufacture the desired protein. Biomanufacturing is used to develop therapeutic proteins, antibiotics, hormones, enzymes, amino acids, blood substitutes, and alcohol for medical use. Businesses have been forced to adopt cutting-edge technologies like single-use bioprocessing techniques because they are affordable and hasten the production process. This is because there aren't many potential new medicines in the pipeline, blockbuster molecules' patents are about to expire, and there's an increased demand for biologics. Better cell culture medium, more advanced feeding strategies, more resilient cell lines, and bioreactor control suited for specific needs are the main upstream development pillars that have led to the field's overall advancement. The growing demand for biopharmaceuticals and the significant role that single-use bioprocessing systems play in reducing the investment costs and R&D expenses associated with the biologics manufacturing process are two factors driving the market's expansion.
List of Prominent Players in the Single-use Upstream Bioprocessing Market:
Danaher Corporation (Cytiva),
Thermo Fisher Scientific, Inc.,
General Electric Company (GE Healthcare),
Rentschler Biopharma SE,
Meissner Filtration Products, Inc.,
Boehringer Ingelheim GmbH,
The demand for biopharmaceuticals is anticipated to rise as the senior population grows across key markets since the aged are more susceptible to chronic illnesses & conditions. Companies increasingly favour single-use bioprocessing systems to meet the rising demand for biopharmaceuticals because they improve process efficiency and cut costs associated with labour-intensive procedures like cleaning, sterilization, and maintenance of steel-based bioreactor systems. Single-use bioprocessing technology is used in a variety of biopharmaceutical applications, including filtration, mixing, purification, upstream expression, storage, and separation. Therefore, the single-use bioprocessing market is expanding. Rising manufacturing techniques' productive capacities, the removal of duplicate processes, direct cost savings from cheap labour and material costs, and reduced energy consumption and water use are all contributing reasons to the market's expansion.
There are currently no clear rules or guidelines governing the contamination of single-use bioprocessing systems by extractables and leachables. Leachables are substances that seep into drug products from packaging, closures, and manufacturing elements, and Leachables can be viewed as a subset of extractable as a result. These extractables and leachables are undesirable goods. Single-use bioprocessing goods frequently experience contamination from the container due to leachables because they are constructed of processed plastic materials. In light of their possible effects on product quality and patient health, considerable concerns regarding extractables and leachables resulting from the components of single-use bioprocessing systems may restrain market expansion.
During the forecast period, North America (the United States, Canada, and Mexico) is expected to lead the market for single-use upstream bioprocessing. The market for single-use bioprocessing is being adopted due to the growing need for biopharmaceuticals and its benefits, including quick deployment, low risk of product cross-contamination, high energy efficiency, and low risk of product cross-contamination, high energy efficiency, and low water usage. The single-use upstream bioprocessing market in North America is anticipated to be dominated by the United States. The development of breakthrough single-use bioprocessing technologies in industrialized nations like the U.S. and Canada, the aging population, and the growing preference for bioactive compounds are all significant market growth drivers in this region.
- In September 2020, Thermo Fisher Scientific expanded its St. Louis facility's capacity for biologics development and production, cell and gene therapy, and pharma product development by investing more than USD 475 million in new capabilities.
- In March 2020, Danaher Corporation announced the completion of its acquisition of the Biopharma business from the Life Sciences division of General Electric Company. The company will be a stand-alone operating company within Danaher's Life Sciences division and will be a part of Danaher under the name Cytiva.